Add once-daily Kerendia to your patients’ current regimen

  • Search-icon-d50032
    01 INITIATION

 

10 mg if:

  • Serum potassium is ≤4.8 mmol/L, or >4.8 to 5.0 mmol/L with additional monitoring*

and

  • eGFR is ≥25 to <60 mL/min/1.73 m2
     

 

20 mg if:

  • Serum potassium is ≤4.8 mmol/L, or >4.8 to 5.0 mmol/L with additional monitoring*

and

  • eGFR is ≥60 mL/min/1.73 m2
     
  • Calender-icon
    02 CHECK LABS


Check serum potassium

and eGFR 4 weeks after:

 

 

  • initiation
  • restart
  • increase in dose

and routinely afterwards

 

  • Tube-icon
    03 TITRATION

Serum potassium

(mmol/L)

10 mg

20 mg

≤4.8

Increase to 20 mg if eGFR has not
decreased >30% compared with the
prior measurement

Maintain dose

>4.8 to 5.5

Maintain dose

Maintain dose

>5.5

Withhold Kerendia and restart at 10 mg when serum
potassium decreases to ≤5.0 mmol/L. Remeasure serum
potassium and eGFR 4 weeks after restart

Withhold Kerendia and restart at 10 mg when serum
potassium decreases to ≤5.0 mmol/L. Remeasure serum
potassium and eGFR 4 weeks after restart

*If serum potassium is >4.8 to 5.0 mmol/L, initiation of Kerendia treatment may be considered with additional serum potassium monitoring within the first 4 weeks based on patient characteristics and serum potassium levels.

 

  • Continue to routinely monitor serum potassium and eGFR, and titrate Kerendia as needed
  • Patients can continue to take commonly prescribed medications including antidiabetic and antihypertensive therapies while on Kerendia
  • Patients with eGFR ≥15 mL/min/1.73 m2 can continue Kerendia treatment with dose adjustment based on serum potassium†

Potassium management

  • There were no dietary restrictions regarding potassium for patients in the FIDELIO-DKD trial and the FIGARO-DKD trial
  • Potassium-lowering therapies (such as sodium polystyrene sulfonate, calcium polystyrene sulfonate, and potassium-binding agents) were allowed in both trials
Discover helpful resources for your patients
    Abbreviationsexpand_less

    †Kerendia should not be initiated in patients with eGFR <25 mL/min/1.73 m2.
     

    eGFR=estimated glomerular filtration rate.

    Referencesexpand_less
    • 1
      Kerendia Prescribing Information, India 2023.
    • 2
      Bakris GL, et al; FIDELIO-DKD Investigators. N Engl J Med. 2020;383(23):2219-2229.
    • 3
      Pitt B, et al. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956.